J J Anker1, M G Kushner2, P Thuras1, J Menk1, A S Unruh1. 1. University of Minnesota - Minneapolis, Department of Psychiatry, United States. 2. University of Minnesota - Minneapolis, Department of Psychiatry, United States. Electronic address: kushn001@umn.edu.
Abstract
BACKGROUND: Epidemiological studies and theory implicate drinking to cope (DTC) with anxiety as a potent moderator of the association between anxiety disorder (AnxD) and problematic alcohol use. However, the relevance of DTC to the treatment of alcohol use disorder (AUD) in those with a co-occurring AnxD has not been well studied. To address this, we examined whether DTC moderates the impact of two therapies: (1) a cognitive behavioral therapy (CBT) designed to reduce DTC and anxiety symptoms; (2) a progressive muscle relaxation training (PMRT) program designed to reduce anxiety symptoms only. METHODS:Patients undergoing a standard AUD residential treatment with a co-occurring AnxD (N=218) were randomly assigned to also receive either the CBT or PMRT. DTC in the 30 days prior to treatment was measured using the Unpleasant Emotions subscale of the Inventory of Drinking Situations. RESULTS: Confirming the predicted moderator model, the results indicated a significant interaction between treatment group and level of pre-treatment DTC behavior. Probing this interaction revealed that for those reporting more pre-treatment DTC behavior, 4-month alcohol outcomes were superior in the CBT group relative to the PMRT group. For those reporting less pre-treatment DTC behavior, however, 4-month alcohol outcomes were similar and relatively good in both treatment groups. CONCLUSIONS: These findings establish a meaningful clinical distinction among those with co-occurring AUD-AnxD based on the degree to which the symptoms of the two disorders are functionally linked through DTC. Those whose co-occurring AUD-AnxD is more versus less strongly linked via DTC are especially likely to benefit from standard AUD treatment that is augmented by a brief CBT designed to disrupt this functional link.
RCT Entities:
BACKGROUND: Epidemiological studies and theory implicate drinking to cope (DTC) with anxiety as a potent moderator of the association between anxiety disorder (AnxD) and problematic alcohol use. However, the relevance of DTC to the treatment of alcohol use disorder (AUD) in those with a co-occurring AnxD has not been well studied. To address this, we examined whether DTC moderates the impact of two therapies: (1) a cognitive behavioral therapy (CBT) designed to reduce DTC and anxiety symptoms; (2) a progressive muscle relaxation training (PMRT) program designed to reduce anxiety symptoms only. METHODS:Patients undergoing a standard AUD residential treatment with a co-occurring AnxD (N=218) were randomly assigned to also receive either the CBT or PMRT. DTC in the 30 days prior to treatment was measured using the Unpleasant Emotions subscale of the Inventory of Drinking Situations. RESULTS: Confirming the predicted moderator model, the results indicated a significant interaction between treatment group and level of pre-treatment DTC behavior. Probing this interaction revealed that for those reporting more pre-treatment DTC behavior, 4-month alcohol outcomes were superior in the CBT group relative to the PMRT group. For those reporting less pre-treatment DTC behavior, however, 4-month alcohol outcomes were similar and relatively good in both treatment groups. CONCLUSIONS: These findings establish a meaningful clinical distinction among those with co-occurring AUD-AnxD based on the degree to which the symptoms of the two disorders are functionally linked through DTC. Those whose co-occurring AUD-AnxD is more versus less strongly linked via DTC are especially likely to benefit from standard AUD treatment that is augmented by a brief CBT designed to disrupt this functional link.
Authors: Matt G Kushner; Eric W Maurer; Paul Thuras; Chris Donahue; Brenda Frye; Kyle R Menary; Jennifer Hobbs; Angela M Haeny; Joani Van Demark Journal: J Consult Clin Psychol Date: 2012-12-31
Authors: Rosa M Crum; Ramin Mojtabai; Samuel Lazareck; James M Bolton; Jennifer Robinson; Jitender Sareen; Kerry M Green; Elizabeth A Stuart; Lareina La Flair; Anika A H Alvanzo; Carla L Storr Journal: JAMA Psychiatry Date: 2013-07 Impact factor: 21.596
Authors: Justin J Anker; Miriam K Forbes; Zack W Almquist; Jeremiah S Menk; Paul Thuras; Amanda S Unruh; Matt G Kushner Journal: J Abnorm Psychol Date: 2017-02-09
Authors: Braden K Linn; Paul R Stasiewicz; Junru Zhao; Joseph F Lucke; Melanie U Ruszczyk; Charles LaBarre; Clara M Bradizza Journal: J Stud Alcohol Drugs Date: 2021-09 Impact factor: 3.346
Authors: Justin J Anker; Erich Kummerfeld; Alexander Rix; Scott J Burwell; Matt G Kushner Journal: Alcohol Clin Exp Res Date: 2018-11-25 Impact factor: 3.455
Authors: Todd J Farchione; Hayley E Fitzgerald; Andrew Curreri; Amy C Janes; Matthew W Gallagher; Sophia Sbi; Elizabeth H Eustis; David H Barlow Journal: Contemp Clin Trials Date: 2021-07-17 Impact factor: 2.261